United Therapeutics sells treatments for pulmonary hypertension and grows transplant organs.
United Therapeutics Corporation (UTHR) is expected to report earnings on Wednesday, November 4, 2026, before the open. Estimated release time 06:33 ET. Consensus EPS estimate is $6.54.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-08-05 | FY2026 Q2 | $6.86 | $7.27 | +6.0% | $783.30M |
| 2026-05-06 | FY2026 Q1 | $7.00 | $5.82 | -16.9% | $781.50M |
| 2026-02-25 | FY2025 Q4 | $7.13 | $7.70 | +8.0% | $790.20M |
| 2025-10-29 | FY2025 Q3 | $6.89 | $7.16 | +3.9% | $799.50M |
| 2025-07-30 | FY2025 Q2 | $7.29 | $6.41 | -12.1% | $798.60M |
| 2025-04-30 | FY2025 Q1 | $6.29 | $6.63 | +5.4% | $794.40M |
| 2025-02-26 | FY2024 Q4 | $6.40 | $6.19 | -3.3% | $735.90M |
| 2024-10-30 | FY2024 Q3 | $6.43 | $6.39 | -0.6% | $748.90M |
UTHR has beaten consensus EPS in 4 of its last 8 reported quarters.
UTHR reported Aug 5. The highlights: EPS of $7.27 — a beat vs the $6.86 estimate (+6%); revenue of $783M — a miss vs the $805M consensus (-3%). Focus now shifts to Tyvaso growth and pipeline.
See UTHR on the live calendar →